Eli Lilly Stock Price Forecast: LLY Detonates 9.95% to $936 With $1,170 Target as Q1 Revenue Smashes $19.8B

Eli Lilly Stock (NYSE:LLY) ripping +9.95% to $936.22, an explosive +$84.75 single-day move off the $851.47 prior close that has the entire pharma complex scrambling to chase the tape higher. The intraday range stretched from a low of $896.80 to a session high of $936.15, and virtually every meaningful tick of the day printed in the green from the cash open onward. Market capitalization has been catapulted to $882.56 billion, the price-to-earnings multiple sits at 40.75, the dividend yield rounds to 0.74%, and the year range — $623.78 to $1,133.95 — captures just how violently this stock has whipsawed over the past twelve months between euphoria and skepticism. Average daily volume of 2.85 million shares is being absolutely dwarfed by today's flow, and the technical character of the chart has flipped in a single session from "stock that lost its mojo after the November 2025 peak near $1,075" to "stock that just reclaimed its growth narrative with both fists." The structural takeaway is straightforward and worth saying plainly: this is the kind of print that resets the entire investment thesis, and the price action is mechanically validating that reset in real time rather than waiting for analysts to upgrade their models on Monday morning. The bears who spent the past five months arguing that Lilly's growth story had peaked are watching that thesis disintegrate on a tape that gives them no place to hide. This is exactly the kind of session that separates the patient longs from the impatient ones.

Q1 2026 by the Numbers: $19.8 Billion Revenue, $8.26 EPS, and a Guidance Raise That Crushed the Skeptics

The actual quarterly figures are the foundation of why LLY is up nearly 10% in a single session, and the math deserves to be laid out without sugar-coating because the magnitude is genuinely difficult to overstate. Revenue printed at $19.8 billion, a staggering +56% year-over-year growth rate, demolishing the consensus that had been hovering near $17.84 billion by close to two billion dollars on the top line alone. Earnings per share landed at $8.26, a brutal +170% year-over-year surge that left the entire sell-side scrambling to revise — and that figure already absorbed a $0.52 in-process R&D write-down, meaning the underlying operational EPS was even hotter than the headline reads. Net income surged +155% to $7.66 billion, a number that converts to free cash flow at a rate the rest of pharma can only dream about. The board did not stop at the headline beats. Full-year 2026 revenue guidance was lifted from the prior $80 billion to $83 billion band to a fresh $82 billion to $85 billion range, with the midpoint at $83.5 billion representing roughly +28% year-over-year growth, a step-up from the prior guide's implied +25%. The non-GAAP EPS guide was simultaneously hiked to $35.50 to $37.00 from the prior $33.50 to $35.00 range. That is a textbook beat-and-raise in its purest form, and the stock's reaction is the market saying — finally, the operational performance has caught up with the valuation, and now the valuation has runway to expand again from this base. This is not a stock that beat by a few pennies and lifted the guide modestly. This is a company saying out loud that the franchise momentum is accelerating rather than decelerating, and the multi-quarter trend is genuinely back on the table.

The Tirzepatide Engine — Mounjaro and Zepbound Now Drive 65% of the Entire Revenue Base

The single most important number on the entire quarterly print is concentration, and the way to interpret it depends entirely on whether the trajectory is accelerating or decelerating — and the data answers that question definitively. Zepbound generated $8.7 billion in Q1 alone, accounting for 44% of total revenue, while Mounjaro contributed $4.2 billion, or another 21%. Combined, the two tirzepatide-derived assets now make up 65% of all of Eli Lilly's revenue, a level of franchise concentration that most chief financial officers would lose sleep over — but the growth rates explain why management is sleeping just fine through the night. Mounjaro revenue exploded +125% year-over-year, and Zepbound jumped +80% year-over-year on a base that was already enormous. The company's share of total prescriptions in the incretin analogs market has now climbed past 60%, while archrival Novo Nordisk (NVO)'s share has compressed to roughly 39%. Every other meaningful asset on the income statement is dwarfed by these two — heart failure drug Jardiance generated $1.1 billion, breast cancer drug Verzenio chipped in $1.3 billion, and the rest of the portfolio fills in the remainder. The cardiometabolic division as a whole pulled in $15.76 billion, oncology delivered $2.3 billion, immunology added $1.2 billion, and neuroscience came in at $382 million. At the current trajectory, the tirzepatide franchise alone could clear $50 billion in 2026 revenue — a number that almost no other single-molecule franchise in pharmaceutical history has approached. That is not a concentration risk. That is a structural moat dressed up as a concentration risk by people who do not understand what dominance actually looks like in pharmaceuticals.

Foundayo: The Round-One Loss That Doesn't Decide a Twelve-Round Fight

The narrative thread that has been weighing on Eli Lilly Stock (NYSE:LLY) since early April is the launch performance of Foundayo (orforglipron), the company's once-daily oral GLP-1 receptor agonist that received FDA approval on April 1 with shipments beginning April 6. Early script data delivered a clear punch — Foundayo registered roughly 3,700 prescriptions through its second week on the market, compared to Novo Nordisk's oral Wegovy clearing 18,000+ in its early window. That gap caused a -4% drop in LLY while NVO rallied +5% when the data dropped, and it is the single biggest reason the stock had compressed from the $1,075 November peak down toward the $880 zone before today's session. But the early-script lens is genuinely misleading and the patient longs have been calling that out for weeks. Foundayo arrives with structural advantages that compound dramatically over time. As a small molecule, it can be manufactured at fundamentally different cost economics versus a peptide like semaglutide — that is a chemistry advantage that does not show up in week-two prescription counts but absolutely shows up in five-year gross margin trajectories. The dosing profile is also flexible — Foundayo can be taken any time of day with or without food or water restrictions, while oral Wegovy requires a strict empty-stomach protocol that meaningfully reduces real-world compliance. Mean weight loss data from the pivotal trials shows Wegovy at roughly 16.6% versus Foundayo at approximately 12.4% — a measurable gap, but the cross-trial methodology differences make a head-to-head read imperfect, and the ≥20% weight loss rate comparison is where Wegovy genuinely separates itself for the moment. Where Foundayo wins decisively is the ACHIEVE-3 trial published in The Lancet, where the asset beat oral semaglutide on Type 2 Diabetes endpoints at the doses tested. The all-cause mortality hazard ratio of 0.43 from ACHIEVE-4 is a potential label-expansion lever that almost no model has fully priced in. Foundayo's annual peak revenue projections range from Bloomberg consensus near $18 billion by 2030 to RBC Capital's significantly more aggressive $36 billion+ call, with management's internal trajectory consistent with $1.5 billion to $2.8 billion in 2026 alone. Today's print did not require Foundayo to be the immediate winner — the underlying franchise was strong enough to deliver the beat-and-raise without it, which is precisely the asymmetric setup the patient long thesis has been built on for months. The longer-tail dynamic is the entire game here. Some early Foundayo prescriptions are treatment-naïve obesity patients, but as the product matures, a meaningful share of the volume will be switchers from injectables — and Lilly's Zepbound has a major volume advantage over Wegovy on the injectable side that mechanically tilts the switcher math toward Foundayo over time.

The FDA Just Killed the Compounding Loophole — That's a Multi-Billion-Dollar Tailwind

A regulatory development arrived alongside the earnings print that genuinely matters and almost nobody is highlighting with sufficient emphasis on the financial-news circuit. The FDA has formally moved to exclude both tirzepatide and semaglutide from the 503B bulks list, meaning licensed outsourcing facilities can no longer legally produce compounded versions of these drugs going forward. This decision rips a major channel of competition out of the market — companies like Hims and Hers Health (HIMS) had been exploiting the loophole that allowed compounding during shortage periods to sell direct-to-consumer compounded GLP-1 products, and Novo Nordisk explicitly cited compounding as a meaningful drag on its operational performance over the past year. With the bulk substances list ruling now formalized, that gray market is effectively moribund. Branded supply normalization plus the elimination of the unregulated copy market is a multi-billion-dollar tailwind that flows directly into both LLY and NVO revenue lines, and Eli Lilly is structurally positioned to capture the larger slice of that flow given its commanding 60%+ prescription share. Add to that the FDA disclosure of impurities found in compounded tirzepatide products, which damages the safety reputation of the entire compounding category and gives prescribers a clean rationale to redirect patients to the branded product. This is a tailwind that will compound over the next twelve to eighteen months as the gray-market patient base gets reabsorbed into branded prescription volume.

The $50 Billion Manufacturing Build Is the Real Moat Nobody Talks About

The piece of the structural thesis that gets dramatically underappreciated by the trading desks is the manufacturing buildout. Eli Lilly has committed roughly $50 billion in CapEx across primarily US-based manufacturing sites, including a $3.5 billion+ Pennsylvania facility explicitly designed for next-generation obesity assets like retatrutide. The 2025 free cash flow margin of just 14% is not a fundamentals problem — it is the direct cost of building this manufacturing fortress, and as those plants come online and CapEx normalizes through 2027 and 2028, the free cash flow margin should expand structurally toward the mid-to-high 20s. Once those facilities are operational, the economies of scale make it nearly impossible for generic manufacturers to compete on price when patent expiry hits around 2036 for the tirzepatide franchise. The fact that LLY has already proactively slashed Zepbound and Mounjaro pricing to as low as ~$350 per month through agreements with the US government, and secured exemption from President Trump's most-favored-nation drug pricing policies through this domestic manufacturing commitment, fundamentally rewires the patent cliff math that bears have been waving around for two years. Generic entrants will struggle to undercut a franchise that has already preemptively priced down to mass-market levels and built scale advantages that small generic shops simply cannot match. That is a structural moat in its purest form, not a marketing claim, and it is the single most valuable asset on the balance sheet that does not show up explicitly in any line item.

The M&A Spree: $18 Billion of Pipeline Optionality Bought in a Single Quarter

The capital allocation strategy underneath the headline numbers tells you everything about how management thinks about future-proofing the franchise beyond the GLP-1 cycle. Eli Lilly completed four acquisitions in Q1 2026, deploying capital across emerging therapeutic modalities: Orna Therapeutics at $2.4 billion for in vivo cell therapy, Kelonia at $7 billion for in vivo CAR-T cell therapy (with Kelonia's lead asset KLN-1010 being a Phase 1 in vivo anti-BCMA CAR-T for multiple myeloma that already carries strategic ties to a J&J in vivo CAR-T collaboration signed in 2025 plus an Astellas/Xyphos research-license agreement covering two programs), narcolepsy specialist Centessa Pharmaceuticals at $6.3 billion plus contingent value rights of up to $1.5 billion, and myelofibrosis/polycythemia vera developer Ajax Therapeutics at $2.3 billion. Combined deal value across the quarter is north of $18 billion before contingencies. LLY is deliberately avoiding mega-money pharma roll-up deals — the kind of strategy that vaporized Pfizer (PFE)'s post-COVID warchest, with PFE down more than 30% on a five-year basis — and is instead buying platform optionality at earlier development stages where the price tags are smaller and the optionality is larger. Combined with the Verve Therapeutics in vivo gene therapy acquisition completed previously, the company is now positioned across in vivo cell therapy, CAR-T platforms, oncology platform expansion, neuroscience, and immunology. The total cash generation backing all of this M&A is the real heart of the thesis — $20.6 billion in 2025 income, roughly $8 billion in Q1 2026 alone, and the trajectory pointing toward $100 billion+ in annual revenue by 2028 if the current growth rate holds. That is a war chest that almost no other pharma can match in absolute dollar terms.

Retatrutide: The "Triple-G" That Could Eclipse Both Foundayo and Zepbound

The pipeline asset that genuinely has the potential to redefine the Eli Lilly Stock (NYSE:LLY) narrative is retatrutide, the next-generation injectable that targets GIP, GLP-1, and glucagon receptors simultaneously — earning it the "Triple G" nickname across the pharma research community. Phase 3 diabetes data from March showed A1C reductions of 1.7% to 2.0%, performance that may be superior to metformin, and weight loss of up to 16.8% at 40 weeks in T2D patients. The NDA filing is currently slated for late 2026, with multiple TRIUMPH data readouts expected throughout the year that could materially move the stock at each milestone. If the data continues to track at this level, retatrutide opens up applications in cardiovascular disease, neuroscience indications, and even nascent markets like alcohol use disorder where GLP-1 mechanisms are showing intriguing early signal. Layered on top of an already-blockbuster tirzepatide franchise and the oral Foundayo asset, retatrutide is the kind of optionality that justifies premium multiples in pharma names because it represents real franchise expansion rather than franchise replacement — three distinct molecules attacking adjacent markets through related but differentiated mechanisms. That is a portfolio architecture that almost no other obesity/diabetes player can match, and it is the architectural reason the long thesis on Lilly continues to have legs even after the stock has already run substantially.

The Pipeline Beyond GLP-1 — Oncology, Immunology, and Neuroscience All Loaded

Concentration risk in tirzepatide gets dramatically reduced when the rest of the pipeline is brought into view, and the pipeline is genuinely deeper than the typical bear narrative acknowledges. KRAS-targeting olomorasib is positioned for non-small cell lung cancer, the largest oncology end-market by revenue. Remternetug is being developed in Alzheimer's, where Lilly's prior AD therapy Kisunla (approved 2024) was a rare commercial disappointment that the company is actively working to fix with this next-generation candidate. A gene therapy program is targeting Parkinson's disease through the Verve platform. Two immunology candidates, simepdekinra and eltrekibart, are being positioned for indications that collectively represent a $100 billion+ addressable market. Each of those programs is individually capable of producing multi-billion-dollar franchises if clinical data lands, and the combination of cardiometabolic dominance plus oncology, gene therapy, and immunology pipeline expansion is exactly the diversification path that long-term holders have been demanding for two years. The patient capital that has been building positions in LLY through the recent correction is being rewarded today not just for the Q1 print but for the optionality math that the rest of the pipeline represents.

Valuation Math: Why $1,150 to $1,170 Is the Realistic Twelve-Month Target

The valuation framework around LLY has been a moving target as the operational data evolves, but the analytical bookends are clear. A simplified DCF using +18% base revenue growth with a front-loaded growth profile and a 24% steady-state free cash flow margin produced an intrinsic value per share of approximately $970.83 before today's print — that math implied roughly +10% upside from the pre-earnings level. The more aggressive trendline-based valuation framework targeted $1,150 in twelve months, which translated to +24% upside at the $925 entry zone. Today's print arrives with the kind of operational acceleration that pulls forward the timeline on hitting either target rather than pushing it out. Consensus EPS growth estimates project +43% in FY26, +21.6% in FY27, and +16.3% in FY28 — these are diminishing returns in percentage terms, but they remain stable, structurally strong, and protected by genuine market leadership combined with technological moats. The forward non-GAAP P/E sits at +48% above the sector median, but the forward non-GAAP PEG ratio is -27% below the sector median because the earnings growth fully justifies the multiple expansion. The market is essentially saying — pay a premium absolute price for a premium growth profile, and that math continues to work as long as the growth keeps printing at the rate it just demonstrated. Revenues breaking the $100 billion per annum threshold in 2028 is now the realistic base case, not the bull scenario, and at that revenue level the trillion-dollar valuation that LLY briefly carried in late 2025 becomes the floor for where the market cap can settle rather than the ceiling that bears keep predicting it cannot reclaim.

Lilly Versus the Rest of Big Pharma — A Class of One

The relative-strength argument for Eli Lilly Stock (NYSE:LLY) is genuinely striking when stacked against the broader pharma tape. Johnson & Johnson (JNJ) will report higher absolute quarterly revenue at $24.6 billion, but only $15.4 billion of that figure is pharmaceutical sales (the remainder being medtech), and JNJ's annual growth rate sits at roughly +10% versus Lilly's +56%. AbbVie (ABBV) dominates immunology with over $7 billion in Q1 revenue from that segment, but does not have anything approaching Lilly's GLP-1 franchise. AstraZeneca (AZN) delivered $6.8 billion in oncology revenue in Q1 but is not a meaningful threat in cardiometabolic. Novo Nordisk (NVO) is the only direct competitor in the obesity franchise but has been beset by operational issues, with the stock down nearly 40% on a twelve-month basis. Pfizer (PFE) burned through its COVID warchest on M&A that has not delivered tangible pipeline value. The pharma sector's overall growth profile sits in the high-single-digit to low-double-digit range, and LLY is the only mega-cap producing 50%+ growth on a base that already approaches $80 billion annually. That kind of operational outperformance is genuinely rare in the entirety of the global equity market, not just in pharma, and it structurally justifies a premium-multiple compensation that the market has been reluctant to fully extend until today. Today's print is the catalyst that gives institutional capital the green light to reposition.